Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer

MLA

Ahmet Murat Aydin, et al. “Comparative Analysis of Three vs. Four Cycles of Neoadjuvant Gemcitabine and Cisplatin for Muscle Invasive Bladder Cancer.” Urologic Oncology: Seminars and Original Investigations, vol. 40, Oct. 2022, p. 453.e19-453.e26. EBSCOhost, https://doi.org/10.1016/j.urolonc.2022.05.023.

APA

Ahmet Murat Aydin, Salim K. Cheriyan, Richard Reich, Ali Hajiran, Charles C. Peyton, Logan Zemp, Alice Yu, Roger Li, Michael A. Poch, Philippe E. Spiess, Rohit Jain, Jingsong Zhang, Wade J. Sexton, & Scott M. Gilbert. (2022). Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 40, 453.e19-453.e26. https://doi.org/10.1016/j.urolonc.2022.05.023

Chicago

Ahmet Murat Aydin, Salim K. Cheriyan, Richard Reich, Ali Hajiran, Charles C. Peyton, Logan Zemp, Alice Yu, et al. 2022. “Comparative Analysis of Three vs. Four Cycles of Neoadjuvant Gemcitabine and Cisplatin for Muscle Invasive Bladder Cancer.” Urologic Oncology: Seminars and Original Investigations 40 (October): 453.e19-453.e26. doi:10.1016/j.urolonc.2022.05.023.